Literature DB >> 34256903

The role of exhaustion in CAR T cell therapy.

Greg M Delgoffe, Chenqi Xu, Crystal L Mackall, Michael R Green, Stephen Gottschalk, Daniel E Speiser, Dietmar Zehn, Paul A Beavis.   

Abstract

CAR T cell therapy successes are challenged by several mechanisms of resistance including the development of dysfunctional states such as exhaustion. The features of CAR T cell exhaustion, its role in limiting the efficacy of CAR T therapy in both liquid and solid malignancies, and potential strategies to overcome it are discussed. Crown
Copyright © 2021. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34256903     DOI: 10.1016/j.ccell.2021.06.012

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  7 in total

Review 1.  B cell targeting in CAR T cell therapy: Side effect or driver of CAR T cell function?

Authors:  Gregory M Chen; Jan Joseph Melenhorst; Kai Tan
Journal:  Sci Transl Med       Date:  2022-06-22       Impact factor: 19.319

Review 2.  Extracellular vesicle-mediated immunoregulation in cancer.

Authors:  Tomofumi Yamamoto; Yusuke Yamamoto; Takahiro Ochiya
Journal:  Int J Hematol       Date:  2022-08-11       Impact factor: 2.319

3.  Reprogrammed CD8+ T-Lymphocytes Isolated from Bone Marrow Have Anticancer Potential in Lung Cancer.

Authors:  Evgenii G Skurikhin; Olga Pershina; Natalia Ermakova; Angelina Pakhomova; Darius Widera; Mariia Zhukova; Edgar Pan; Lubov Sandrikina; Lena Kogai; Nikolai Kushlinskii; Sergey G Morozov; Aslan Kubatiev; Alexander Dygai
Journal:  Biomedicines       Date:  2022-06-19

4.  Spermidine Promotes Nb CAR-T Mediated Cytotoxicity to Lymphoma Cells Through Elevating Proliferation and Memory.

Authors:  Hongxia Wang; Dan Jiang; Liyuan Liu; Yanting Zhang; Miao Qin; Yuliang Qu; Liyan Wang; Shan Wu; Haijin Zhou; Tao Xu; Guangxian Xu
Journal:  Onco Targets Ther       Date:  2022-10-18       Impact factor: 4.345

Review 5.  Immune Cell Metabolic Fitness for Life.

Authors:  Kevin S Bittman
Journal:  Antibodies (Basel)       Date:  2022-04-30

Review 6.  Experiences with Glofitamab Administration following CAR T Therapy in Patients with Relapsed Mantle Cell Lymphoma.

Authors:  Alexander D Heini; Ulrike Bacher; Naomi Porret; Gertrud Wiedemann; Myriam Legros; Denise Stalder Zeerleder; Katja Seipel; Urban Novak; Michael Daskalakis; Thomas Pabst
Journal:  Cells       Date:  2022-09-02       Impact factor: 7.666

Review 7.  Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response.

Authors:  Dong-Rui Wang; Xian-Lin Wu; Ying-Li Sun
Journal:  Signal Transduct Target Ther       Date:  2022-09-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.